Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ifebemtinib,Garsorasib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
InxMed Reports Positive Results for Ifebemtinib and Garsorasib in NSCLC
Details : InxMed investigational product IN10018 (Ifebemtinib), a FAK inhibitor, is being evaluated in combination with garsorasib, for the first-line treatment of non-small cell lung cancer.
Brand Name : IN10018
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 30, 2024
Lead Product(s) : Ifebemtinib,Garsorasib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : Escugen
Deal Size : Undisclosed
Deal Type : Licensing Agreement
InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs
Details : The license agreement provides InxMed with right to use EZWi-Fit® platform for the development of the next generation tumor-associated antigens targeting ADCs. InxMed will have the right for development, manufacturing, and commercialization of these ADC...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 19, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Escugen
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : OMTX705
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OMTX705 is a novel antibody–drug conjugate (ADC) molecule targeting fibroblast-activating protein alpha, which is investigated for the treatment of hard-to-treat solid tumors.
Brand Name : OMTX705
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 29, 2023
Lead Product(s) : OMTX705
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Oncology
Study Phase : Discovery
Recipient : GeneQuantum Healthcare
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, GeneQuantum will provide InxMed with its globally leading technologies in site-specific glycan conjugation, stable linker small molecule technology, and intelligent continuous conjugation production platform for developing innovative...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 17, 2023
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Oncology
Highest Development Status : Discovery
Recipient : GeneQuantum Healthcare
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Ifebemtinib,Pegylated Liposomal Doxorubicin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The data showed that patients receiving combination of IN10018 (BI 853520) with PLD demonstrated promising antitumor activities and manageable safety profile in PROC patients, with a high overall response rate (ORR) of 56.7%.
Brand Name : BI 853520
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 27, 2022
Lead Product(s) : Ifebemtinib,Pegylated Liposomal Doxorubicin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ifebemtinib,Cobimetinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Hyfinity Investments
Deal Size : $15.0 million
Deal Type : Series B Financing
Details : InxMed will use the funds to accelerate ongoing clinical trials of IN10018 (BI 853520) for multiple cancer types in both US and China, including the initiation of pivotal trials, and advance more stroma targeting pipelines into clinics in both US and Chi...
Brand Name : BI 853520
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 09, 2022
Lead Product(s) : Ifebemtinib,Cobimetinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Hyfinity Investments
Deal Size : $15.0 million
Deal Type : Series B Financing
Details : Early clinical data on IN10018,a highly-selective adenosine triphosphate competitive FAK inhibitor showed its safety and efficacy in multiple tumor types, and latest research results and preclinical data demonstrated that IN10018 can also be effective in...
Brand Name : IN10018
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 14, 2022
Details : IN10018, formerly known as BI853520, is a potent and selective ATP-competitive focal adhesion kinase (FAK) small molecule inhibitor under clinical development stage in United States, Australia, and China.
Brand Name : IN10018
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 19, 2021
Lead Product(s) : Ifebemtinib,Undisclosed
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
US FDA Grants Fast Track Designation to InxMed's IN10018
Details : Early clinical data of IN10018 has demonstrated a favorable safety profile and promising efficacy signals against a number of tumor types.
Brand Name : BI 853520
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 19, 2021
Lead Product(s) : Ifebemtinib,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ifebemtinib,Cobimetinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Ennovation Ventures
Deal Size : $19.0 million
Deal Type : Series A Financing
InxMed Announced the Completion of RMB 130M (~US$ 19M) Series A+ Financing
Details : Funding will support the acceleration of IN10018 clinical program and expand InxMed's portfolio. IN10018 is a potent and selective ATP-competitive focal adhesion kinase small molecule inhibitor.
Brand Name : BI 853520
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 03, 2020
Lead Product(s) : Ifebemtinib,Cobimetinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Ennovation Ventures
Deal Size : $19.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?